Δημοσιεύσεις
1: Moosmann T, Veraar C, Brunner J, Fraedrich G, Frech A, Horninger W, Ratzinger
G, Streif W, Teuchner B, Willeit J, Zlamy M, De Zordo T, Schirmer M. Differential
clinical presentation of Adamantiades-Behçet’s disease in non-endemic and endemic
areas: retrospective data from a Middle-European cohort study. Int J Rheum Dis.
2018 Dec;21(12):2151-2157. doi: 10.1111/1756-185X.13306. Epub 2018 Apr 17. PubMed
PMID: 29664210.
2: Protogerou AD, Nasothimiou EG, Sfikakis PP, Tzioufas AG. Non-invasive vascular
biomarkers in patients with Behçet’s disease: review of the data and future
perspectives. Clin Exp Rheumatol. 2017 Nov-Dec;35 Suppl 108(6):100-107. Epub 2017
Oct 6. Review. PubMed PMID: 29148423.
3: Argyropoulou OD, Protogerou AD, Sfikakis PP. Accelerated atheromatosis and
arteriosclerosis in primary systemic vasculitides: current evidence and future
perspectives. CurrOpinRheumatol. 2018 Jan;30(1):36-43. doi:
10.1097/BOR.0000000000000453. Review. PubMed PMID: 29040156.
4: Sfikakis PP, Arida A, Panopoulos S, Fragiadaki K, Pentazos G, Laskari K,
Tektonidou M, Markomichelakis N. Brief Report: Drug-Free Long-Term Remission in
Severe Behçet’s Disease Following Withdrawal of Successful Anti-Tumor Necrosis
Factor Treatment. Arthritis Rheumatol. 2017 Dec;69(12):2380-2385. doi:
10.1002/art.40235. Epub 2017 Nov 8. PubMed PMID: 28834393.
5: Arida A, Sfikakis PP. Anti-cytokine biologic treatment beyond anti-TNF in
Behçet’s disease. Clin Exp Rheumatol. 2014 Jul-Aug;32(4 Suppl 84):S149-55. Epub
2014 Sep 30. Review. PubMed PMID: 25268669.
6: Vaiopoulos AG, Sfikakis PP, Kanakis MA, Vaiopoulos G, Kaklamanis PG.
Gastrointestinal manifestations of Behçet’s disease: advances in evaluation and
management. Clin Exp Rheumatol. 2014 Jul-Aug;32(4 Suppl 84):S140-8. Epub 2014 Sep
- Review. PubMed PMID: 25268668.
7: Kalra S, Silman A, Akman-Demir G, Bohlega S, Borhani-Haghighi A,
Constantinescu CS, Houman H, Mahr A, Salvarani C, Sfikakis PP, Siva A, Al-Araji
- Diagnosis and management of Neuro-Behçet’s disease: international consensus
recommendations. J Neurol. 2014 Sep;261(9):1662-76. doi:
10.1007/s00415-013-7209-3. Epub 2013 Dec 24. Review. PubMed PMID: 24366648;
PubMed Central PMCID: PMC4155170.
8: Markomichelakis N, Delicha E, Masselos S, Sfikakis PP. Intravitreal infliximab
for sight-threatening relapsing uveitis in Behçet disease: a pilot study in 15
patients. Am J Ophthalmol. 2012 Sep;154(3):534-541.e1. doi:
10.1016/j.ajo.2012.03.035. Epub 2012 Jul 11. PubMed PMID: 22789563.
9: Arida A, Fragiadaki K, Giavri E, Sfikakis PP. Anti-TNF agents for Behçet’s
disease: analysis of published data on 369 patients. Semin Arthritis Rheum. 2011
Aug;41(1):61-70. doi: 10.1016/j.semarthrit.2010.09.002. Epub 2010 Dec 17. Review.
PubMed PMID: 21168186.
10: Markomichelakis N, Delicha E, Masselos S, Fragiadaki K, Kaklamanis P,
Sfikakis PP. A single infliximab infusion vs corticosteroids for acute panuveitis
attacks in Behçet’s disease: a comparative 4-week study. Rheumatology (Oxford).
2011 Mar;50(3):593-7. doi: 10.1093/rheumatology/keq366. Epub 2010 Nov 21. PubMed
PMID: 21097877.
11: Sfikakis PP. The first decade of biologic TNF antagonists in clinical
practice: lessons learned, unresolved issues and future directions. Curr Dir
Autoimmun. 2010;11:180-210. doi: 10.1159/000289205. Epub 2010 Feb 18. Review.
PubMed PMID: 20173395.
12: Arida A, Vaiopoulos G, Markomichelakis N, Kaklamanis P, Sfikakis PP. Are
clusters of patients with distinct clinical expression present in Behçet’s
disease? Clin Exp Rheumatol. 2009 Mar-Apr;27(2 Suppl 53):S48-51. PubMed PMID:
19796533.
13: Hatemi G, Silman A, Bang D, Bodaghi B, Chamberlain AM, Gul A, Houman MH,
Kötter I, Olivieri I, Salvarani C, Sfikakis PP, Siva A, Stanford MR, Stübiger N,
Yurdakul S, Yazici H. Management of Behçet disease: a systematic literature
review for the European League Against Rheumatism evidence-based recommendations
for the management of Behçet disease. Ann Rheum Dis. 2009 Oct;68(10):1528-34.
doi: 10.1136/ard.2008.087957. Epub 2008 Apr 17. Review. PubMed PMID: 18420940.
14: Hatemi G, Silman A, Bang D, Bodaghi B, Chamberlain AM, Gul A, Houman MH,
Kötter I, Olivieri I, Salvarani C, Sfikakis PP, Siva A, Stanford MR, Stübiger N,
Yurdakul S, Yazici H; EULAR Expert Committee. EULAR recommendations for the
management of Behçet disease. Ann Rheum Dis. 2008 Dec;67(12):1656-62. doi:
10.1136/ard.2007.080432. Epub 2008 Jan 31. PubMed PMID: 18245110.
15: Elezoglou A, Kafasi N, Kaklamanis PH, Theodossiadis PG, Kapsimali V, Choremi
E, Vaiopoulos G, Sfikakis PP. Infliximab treatment-induced formation of
autoantibodies is common in Behçet’s disease. Clin Exp Rheumatol. 2007
Jul-Aug;25(4 Suppl 45):S65-9. PubMed PMID: 17949554.
16: Protogerou AD, Sfikakis PP, Stamatelopoulos KS, Papamichael C, Aznaouridis K,
Karatzis E, Papaioannou TG, Ikonomidis I, Kaklamanis P, Mavrikakis M, Lekakis J.
Interrelated modulation of endothelial function in Behcet’s disease by clinical
activity and corticosteroid treatment. Arthritis Res Ther. 2007;9(5):R90. PubMed
PMID: 17845731; PubMed Central PMCID: PMC2212573.
17: Sfikakis PP, Markomichelakis N, Alpsoy E, Assaad-Khalil S, Bodaghi B, Gul A,
Ohno S, Pipitone N, Schirmer M, Stanford M, Wechsler B, Zouboulis C, Kaklamanis
P, Yazici H. Anti-TNF therapy in the management of Behcet’s disease–review and
basis for recommendations. Rheumatology (Oxford). 2007 May;46(5):736-41. Epub
2007 Apr 2. Review. PubMed PMID: 17403712.
18: Sfikakis PP, Iliopoulos A, Elezoglou A, Kittas C, Stratigos A. Psoriasis
induced by anti-tumor necrosis factor therapy: a paradoxical adverse reaction.
Arthritis Rheum. 2005 Aug;52(8):2513-8. PubMed PMID: 16052599.
19: Markomichelakis NN, Theodossiadis PG, Pantelia E, Papaefthimiou S,
Theodossiadis GP, Sfikakis PP. Infliximab for chronic cystoid macular edema
associated with uveitis. Am J Ophthalmol. 2004 Oct;138(4):648-50. PubMed PMID:
15488796.
20: Sfikakis PP, Kaklamanis PH, Elezoglou A, Katsilambros N, Theodossiadis PG,
Papaefthimiou S, Markomichelakis N. Infliximab for recurrent, sight-threatening
ocular inflammation in Adamantiades-Behçet disease. Ann Intern Med. 2004 Mar
2;140(5):404-6. PubMed PMID: 14996689.
21: Katsiari CG, Theodossiadis PG, Kaklamanis PG, Markomichelakis NN, Sfikakis
- Successful long-term treatment of refractory Adamantiades-Behçet’s disease
(ABD) with infliximab: report of two patients. Adv Exp Med Biol. 2003;528:551-5.
PubMed PMID: 12918762.
22: Elezoglou AV, Sfikakis PP, Vaiopoulos G, Kapsimali V, Kaklamanis PG. Serum
levels of soluble TNF-alpha receptor-II (P75), circulating gammadelta T-cells and
Adamantiades-Behçet’s disease activity. Adv Exp Med Biol. 2003;528:261-5. PubMed
PMID: 12918703.
23: Sfikakis PP. Behçet’s disease: a new target for anti-tumour necrosis factor
treatment. Ann Rheum Dis. 2002 Nov;61 Suppl2:ii51-3. Review. PubMed PMID:
12379622; PubMed Central PMCID: PMC1766720.
24: Sfikakis PP, Theodossiadis PG, Katsiari CG, Kaklamanis P, Markomichelakis NN.
Effect of infliximab on sight-threatening panuveitis in Behçet’s disease. Lancet.
2001 Jul 28;358(9278):295-6. PubMed PMID: 11498218.
25: Vaiopoulos G, Sfikakis PP, Hatzinikolaou P, Stamatelos G, Kaklamanis P.
Adamantiadis-Behçet’s disease in sisters. Clin Rheumatol. 1996 Jul;15(4):382-4.
PubMed PMID: 8853173.